Molecular signatures as cancer biomarkers: Methodologic issues in discovery, validation, qualification, and standardization

Field Cancerization: Basic Science and Clinical Applications

Volumn , Issue , 2011, Pages 535-558

  Pritzker, Laura B ^a   Pritzker, Kenneth P H ^b  

^a YorkMedTech Partners Inc   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84895323471     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (108)

1. Dakubo GD, Jakupciak JP, Birch-Machin MA, Parr RL (2007) Clinical implications and utility of field cancerization. Cancer Cell Int. 7: 2.
2. Nelson HD, Huffman LH, Fu R, Harris EL (2005) Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force. Ann. Intern. Med. 143: 362-379.
3. Venkitaraman AR (2009) Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment. Annu. Rev. Pathol. 4: 461-487.
4. Lynch HT, Lynch JF, Attard TA (2009) Diagnosis and management of hereditary colorectal cancer syndromes: Lynch syndrome as a model. CMAJ 181: 273-280.
5. Pritzker KPH (2002) Cancer biomarkers: easier said than done. Clin. Chem. 48: 1147-1150.
6. Pritzker KPH, Azad A (2004) Genomic biomarkers for cancer assessment: implementation challenges for laboratory practice. Clin. Biochem. 37: 642-646.
7. Pritzker KPH, Azad A (2005) Bringing biomarkers to clinical practice. Clinical Lab. International 25: 24.
8. Chigira M, Shinozaki T, Shimizu T, Noda K (1990) No correlation between tumor markers and prognosis under polygenic control systems. MedHypotheses 32: 245-247.
9. Rubin H (1990) The significance of biological heterogeneity. Cancer Metastasis Rev. 9: 1-20.
10. Biomarkers Definitions Working Group B (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69: 89-95.
11. Negm RS, Verma M, Srivastava S (2002) The promise of biomarkers in cancer screening and detection. Trends Mol. Med. 8: 288-293.
12. Wagner JA, Williams SA, Webster CJ (2007) Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clin. Pharmacol. Ther. 81: 104-107.
13. Niedbala RS, Mauck C, Harrison P, Doncel GF (2009) Biomarker discovery: validation and decision-making in product development. Sex Transm. Dis. 36: S76-80.
14. Schulte PA (1989) A conceptual framework for the validation and use of biologic markers. Environ. Res. 48: 129-144.
15. Ransohoff DF (2004) Rules of evidence for cancer molecular-marker discovery and validation. Nat. Rev. Cancer 4: 309-314.
16. Chau CH, Rixe O, McLeod H, Figg WD (2008) Validation of analytic methods for biomarkers used in drug development. Clin. Cancer Res. 14: 5967-5976.
17. Simon R (2008) Development and Validation of Biomarker Classifiers for Treatment Selection. J. Stat. Plan Inference 138: 308-320.
18. Parker A, McCaffery I, Patterson S (2009) Examining molecular biology in humans. Biotechniques 46: 358-360.
19. Mildvan D, Landay A, De GV, Machado SG, Kagan J (1997) An approach to the validation of markers for use in AIDS clinical trials. ClinInfectDis. 24: 764-774.
20. Bauer DC, Hunter DJ, Abramson SB, Attur M, Corr M, et al. (2006) Classification of osteoarthritis biomarkers: a proposed approach. Osteoarthritis Cartilage 14: 723-727.
21. Duffy MJ (2007) Role of tumor markers in patients with solid cancers: A critical review. Eur. J. Intern. Med. 18: 175-184.
22. Shinozaki T, Chigira M, Kato K (1992) Multivariate analysis of serum tumor markers for diagnosis of skeletal metastases. Cancer 69: 108-112.
23. Fernandis AZ, Wenk MR (2009) Lipid-based biomarkers for cancer. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci.
24. Duffy MJ, Napieralski R, Martens JW, Span PN, Spyratos F, et al. (2009) Methylated genes as new cancer biomarkers. Eur. J. Cancer 45: 335-346.
25. Gelato KA, Fischle W (2008) Role of histone modifications in defining chromatin structure and function. Biol. Chem. 389: 353-363.
26. Armstrong SA, Golub TR, Korsmeyer SJ (2003) MLL-rearranged leukemias: insights from gene expression profiling. Semin. Hematol. 40: 268-273.
27. Mistry AR, Pedersen EW, Solomon E, Grimwade D (2003) The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the disease. Blood Rev. 17: 71-97.
28. Lehrmann H, Pritchard LL, Harel-Bellan A (2002) Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation. Adv. Cancer Res. 86: 41-65.
29. Schiess R, Wollscheid B, Aebersold R (2009) Targeted proteomic strategy for clinical biomarker discovery. Mol. Oncol. 3: 33-44.
30. Hartmann O, Spyratos F, Harbeck N, Dietrich D, Fassbender A, et al. (2009) DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy. Clin. Cancer Res. 15: 315-323.
31. van der Kwast TH, Bapat B (2009) Predicting favourable prognosis of urothelial carcinoma: gene expression and genome profiling. Curr. Opin. Urol. 19: 516-521.
32. Taylor IW, Linding R, Warde-Farley D, Liu Y, Pesquita C, et al. (2009) Dynamic modularity in protein interaction networks predicts breast cancer outcome. Nat. Biotechnol. 27: 199-204.
33. Sun Y, Goodison S (2009) Optimizing molecular signatures for predicting prostate cancer recurrence. Prostate 69: 1119-1127.
34. Lee JW, Devanarayan V, Barrett YC, Weiner R, Allinson J, et al. (2006) Fit-for-purpose method development and validation for successful biomarker measurement. Pharm. Res. 23: 312-328.
35. De Gruttola VG, Clax P, DeMets DL, Downing GJ, Ellenberg SS, et al. (2001) Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop. Control ClinTrials 22: 485-502.
36. Taylor JM, Ankerst DP, Andridge RR (2008) Validation of biomarker-based risk prediction models. Clin. Cancer Res. 14: 5977-5983.
37. Bild AH, Parker JS, Gustafson AM, Acharya CR, Hoadley KA, et al. (2009) An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer. Breast Cancer Res 11: R55.
38. Gupta AK, Brenner DE, Turgeon DK (2008) Early detection of colon cancer: new tests on the horizon. Mol. Diagn. Ther. 12: 77-85.
39. Pavlou M, Diamandis EP (2009) The search for new prostate cancer biomarkers continues. Clin. Chem. 55: 1277-1279.
40. Makarov DV, Loeb S, Getzenberg RH, Partin AW (2008) Biomarkers for Prostate Cancer. Annu. Rev. Med.
41. Sotiriou C, Pusztai L (2009) Gene-expression signatures in breast cancer. N. Engl. J. Med. 360: 790-800.
42. Easton DF, Eeles RA (2008) Genome-wide association studies in cancer. Hum. Mol. Genet. 17: R109-115.
43. Best CJ, Gillespie JW, Englert CR, Swalwell JI, Pfeifer J, et al. (2000) New approaches to molecular profiling of tissue samples. AnalCell Pathol. 20: 1-6.
44. Rai AJ, Kamath RM, Gerald W, Fleisher M (2009) Analytical validation of the GeXP analyzer and design of a workflow for cancer-biomarker discovery using multiplexed gene-expression profiling. Anal. Bioanal. Chem. 393: 1505-1511.
45. Saleh EM, El-Awady RA, Abdel Alim MA, Abdel Wahab AH (2009) Altered Expression of Proliferation-Inducing and Proliferation-Inhibiting Genes Might Contribute to Acquired Doxorubicin Resistance in Breast Cancer Cells. Cell Biochem.
46. Emmert-Buck MR, Strausberg RL, Krizman DB, Bonaldo MF, Bonner RF, et al. (2000) Molecular profiling of clinical tissue specimens: feasibility and applications. Am. J. Pathol. 156: 1109-1115.
47. Tian Q, Stepaniants SB, Mao M, Weng L, Feetham MC, et al. (2004) Integrated genomic and proteomic analyses of gene expression in Mammalian cells. Mol. Cell Proteomics 3: 960-969.
48. Rautio JJ, Kataja K, Satokari R, Penttila M, Soderlund H, et al. (2006) Rapid and multiplexed transcript analysis of microbial cultures using capillary electophoresis-detectable oligonucleotide probe pools. J. Microbiol. Methods 65: 404-416.
49. Estilo CL, P Oc, Talbot S, Socci ND, Carlson DL, et al. (2009) Oral tongue cancer gene expression profiling: Identification of novel potential prognosticators by oligonucleotide microarray analysis. BMC Cancer 9: 11.
50. Wong SC, Chan CM, Ma BB, Lam MY, Choi GC, et al. (2009) Advanced proteomic technologies for cancer biomarker discovery. Expert Rev. Proteomics 6: 123-134.
51. Hood BL, Stewart NA, Conrads TP (2009) Development of high-throughput mass spectrometry-based approaches for cancer biomarker discovery and implementation. Clin. Lab. Med. 29: 115-138.
52. McIntosh M, Fitzgibbon M (2009) Biomarker validation by targeted mass spectrometry. Nat. Biotechnol. 27: 622-623.
53. Simpson KL, Whetton AD, Dive C (2009) Quantitative mass spectrometry-based techniques for clinical use: biomarker identification and quantification. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 877: 1240-1249.
54. Li G, Zhang W, Zeng H, Chen L, Wang W, et al. (2009) An integrative multi-platform analysis for discovering biomarkers of osteosarcoma. BMC Cancer 9: 150.
55. Cadron I, Van Gorp T, Amant F, Vergote I, Moerman P, et al. (2009) The use of laser microdissection and SELDI-TOF MS in ovarian cancer tissue to identify protein profiles. Anticancer Res. 29: 1039-1045.
56. Seliger B, Dressler SP, Wang E, Kellner R, Recktenwald CV, et al. (2009) Combined analysis of transcriptome and proteome data as a tool for the identification of candidate biomarkers in renal cell carcinoma. Proteomics 9: 1567-1581.
57. Dudoit S, Fridlyand J (2003) Classification in microarray experiments. In: Speed T, (editor.) Statistical Analysis of Gene Expression Microarray Data. New York: Chapman and Hall, CRC Press. pp. 93-158.
58. Sun Y, Urquidi V, Goodison S (2009) Derivation of molecular signatures for breast cancer recurrence prediction using a two-way validation approach. Breast Cancer Res.
59. Veltri RW, Miller MC, An G (2001) Standardization, analytical validation, and quality control of intermediate endpoint biomarkers. Urology 57: 164-170.
60. Nosov V, Su F, Amneus M, Birrer M, Robins T, et al. (2009) Validation of serum biomarkers for detection of early-stage ovarian cancer. Am. J. Obstet. Gynecol. 200: 639 e631-635.
61. Hoos A, Urist MJ, Stojadinovic A, Mastorides S, Dudas ME, et al. (2001) Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am. J. Pathol. 158: 1245-1251.
62. Hewitt SM (2009) Tissue microarrays as a tool in the discovery and validation of tumor markers. Methods Mol. Biol. 520: 151-161.
63. Camp RL, Neumeister V, Rimm DL (2008) A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers. J. Clin. Oncol. 26: 5630-5637.
64. van der Vegt B, de Bock GH, Hollema H, Wesseling J (2009) Microarray methods to identify factors determining breast cancer progression: potentials, limitations, and challenges. Crit. Rev. Oncol. Hematol. 70: 1-11.
65. Lexe G, Monaco J, Doyle S, Basavanhally A, Reddy A, et al. (2009) Towards improved cancer diagnosis and prognosis using analysis of gene expression data and computer aided imaging. Exp. Biol. Med. (Maywood) 234: 860-879.
66. Fons G, van der Velden J, Burger M, ten Kate F (2009) Validation of tissue microarray technology in vulvar cancer. Int. J. Gynecol. Pathol. 28: 76-82.
67. Lucas JE, Carvalho CM, Chen JL, Chi JT, West M (2009) Cross-study projections of genomic biomarkers: an evaluation in cancer genomics. PLoS One 4: e4523.
68. Reyal F, van Vliet MH, Armstrong NJ, Horlings HM, de Visser KE, et al. (2008) A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer. Breast Cancer Res. 10: R93.
69. Sole X, Bonifaci N, Lopez-Bigas N, Berenguer A, Hernandez P, et al. (2009) Biological convergence of cancer signatures. PLoS One 4: e4544.
70. Wagner JA (2002) Overview of biomarkers and surrogate endpoints in drug development. Dis. Markers 18: 41-46.
71. Mandrekar SJ, Sargent DJ (2009) Clinical trial designs for predictive biomarker validation: one size does not fit all. J. Biopharm. Stat. 19: 530-542.
72. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344: 783-792.
73. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, et al. (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20: 719-726.
74. Wu X, Hawse JR, Subramaniam M, Goetz MP, Ingle JN, et al. (2009) The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells. Cancer Res. 69: 1722-1727.
75. Hornick JL, Fletcher CD (2007) The role of KIT in the management of patients with gastrointestinal stromal tumors. Hum. Pathol. 38: 679-687.
76. Cassier PA, Dufresne A, Arifi S, El Sayadi H, Labidi I, et al. (2008) Imatinib mesilate for the treatment of gastrointestinal stromal tumour. Expert Opin. Pharmacother 9: 1211-1222.
77. Lasota J, Miettinen M (2008) Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology 53: 245-266.
78. Mack GS (2009) FDA holds court on post hoc data linking KRAS status to drug response. Nat. Biotechnol. 27: 110-112.
79. Sheridan C (2008) EGFR inhibitors embrace KRAS. Nat. Biotechnol. 26: 839-840.
80. Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, et al. (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol. 26: 374-379.
81. Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, et al. (2008) First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J. Clin. Oncol. 26: 2442-2449.
82. Goncalves A, Esteyries S, Taylor-Smedra B, Lagarde A, Ayadi M, et al. (2008) A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment. BMC Cancer 8: 169.
83. Druker BJ (2003) Imatinib alone and in combination for chronic myeloid leukemia. Semin. Hematol. 40: 50-58.
84. Deininger MW (2003) Cytogenetic studies in patients on imatinib. Semin. Hematol. 40: 50-55.
85. Jabbour E, Cortes J, O'Brien S, Giles F, Kantarjian H (2007) New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance. Semin. Hematol. 44: S25-31.
86. Gokbuget N, Hoelzer D (2009) Treatment of adult acute lymphoblastic leukemia. Semin. Hematol. 46: 64-75.
87. Buyse M, Loi S, van't Veer L, Viale G, Delorenzi M, et al. (2006) Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J. Natl. Cancer Inst. 98: 1183-1192.
88. Brauch H, Murdter TE, Eichelbaum M, Schwab M (2009) Pharmacogenomics of tamoxifen therapy. Clin. Chem. 55: 1770-1782.
89. Paik S, Tang G, Shak S, Kim C, Baker J, et al. (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol. 24: 3726-3734.
90. EGAPP (2009) Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer? Genet. Med. 11: 66-73.
91. Bartlett JM, Campbell FM, Mallon EA (2008) Determination of HER2 amplification by in situ hybridization: when should chromosome 17 also be determined? Am. J. Clin. Pathol. 130: 920-926.
92. Chibon F, de Mascarel I, Sierankowski G, Brouste V, Bonnefoi H, et al. (2009) Prediction of HER2 gene status in Her2 2+ invasive breast cancer: a study of 108 cases comparing ASCO/CAP and FDA recommendations. Mod. Pathol. 22: 403-409.
93. Rogers M, Dore JH, Grunkin M, Pritzker KPH. Advancing breast cancer HER2 FISH quality by image analysis (abstract) 2009 December 9-13, 2009; San Antonio, Texas, USA.
94. Vance GH, Barry TS, Bloom KJ, Fitzgibbons PL, Hicks DG, et al. (2009) Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Arch. Pathol. Lab. Med. 133: 611-612.
95. Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, et al. (2007) The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 101: 113-121.
96. Jin Y, Desta Z, Stearns V, Ward B, Ho H, et al. (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl. Cancer Inst. 97: 30-39.
97. Punglia RS, Burstein HJ, Winer EP, Weeks JC (2008) Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J. Natl. Cancer Inst. 100: 642-648.
98. Girault I, Bieche I, Lidereau R (2006) Role of estrogen receptor alpha transcriptional coregulators in tamoxifen resistance in breast cancer. Maturitas 54: 342-351.
99. Jansen MP, Foekens JA, van Staveren IL, Dirkzwager-Kiel MM, Ritstier K, et al. (2005) Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J. Clin. Oncol. 23: 732-740.
100. Meijer D, Jansen MP, Look MP, Ruigrok-Ritstier K, van Staveren IL, et al. (2009) TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancer. Breast Cancer Res. Treat. 113: 253-260.
101. Sturgeon CM (2001) Tumor markers in the laboratory: closing the guideline-practice gap. Clin. Biochem. 34: 353-359.
102. FDA (2007) Draft guidance for industry, clinical laboratories, and FDA staff: in vitro diagnostic multivariate index assays. In: Administration FD, editor: FDA.
103. CAP (2009) Laboratory-developed test oversight model.
104. Monzon FA, Ogino S, Hammond ME, Halling KC, Bloom KJ, et al. (2009) The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer. Arch. Pathol. Lab. Med. 133: 1600-1606.
105. Bos JL (1989) ras oncogenes in human cancer: a review. Cancer Res. 49: 4682-4689.
106. Ko JM, Cheung MH, Wong CM, Lau KW, Tang CM, et al. (1998) Ki-ras codon 12 point mutational activation in Hong Kong colorectal carcinoma patients. Cancer Lett. 134: 169-176.
107. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, et al. (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 66: 3992-3995.
108. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, et al. (2009) American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J. Clin. Oncol. 27: 2091-2096.